Tonix Pharmaceuticals Holding Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Cover
Financial Statements
Notes to Financial Statements
Accounting Policies
- SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY

LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY	9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY	NOTE 13 – LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY On February 13, 2023, Tonix exercised an option to obtain an exclusive license from Columbia University (“Columbia) for the development of a portfolio of both fully human and murine mAbs for the treatment or prophylaxis of SARS-CoV-2 infection, including our TNX-3600 and TNX-4100 product candidates, respectively. The licensed mAbs were developed as part of a research collaboration and option agreement between Tonix and Columbia. As of September 30, 2024, other than the upfront fee, no payments have been accrued or paid in relation to this agreement.

LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY

9 Months Ended

Sep. 30, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY

NOTE 13 – LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY

On February 13, 2023, Tonix exercised an option to obtain an exclusive license from Columbia University (“Columbia) for the development of a portfolio of both fully human and murine mAbs for the treatment or prophylaxis of SARS-CoV-2 infection, including our TNX-3600 and TNX-4100 product candidates, respectively. The licensed mAbs were developed as part of a research collaboration and option agreement between Tonix and Columbia. As of September 30, 2024, other than the upfront fee, no payments have been accrued or paid in relation to this agreement.